Literature DB >> 8306567

Estimation of creatinine clearance in patients with gynecologic cancer.

T Tsubaki1, S Goodin, W G Leader, M H Chandler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8306567

Source DB:  PubMed          Journal:  Clin Pharm        ISSN： 0278-2677


× No keyword cloud information.
  7 in total

Review 1.  Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge.

Authors:  Karin Holweger; Carsten Bokemeyer; Hans-Peter Lipp
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

2.  Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Authors:  Dolores Santos Buelga; María del Mar Fernandez de Gatta; Emma V Herrera; Alfonso Dominguez-Gil; María José García
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Relationship between pharmacokinetic parameters of gentamicin and patient characteristics and/or clinical data in patients with solid organ tumours.

Authors:  A Ortega; A Aldaz; J Giráldez; A Brugarolas
Journal:  Pharm World Sci       Date:  1999-10

Review 4.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

5.  Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer.

Authors:  Bercin Kutluk Cenik; Han Sun; David E Gerber
Journal:  Lung Cancer       Date:  2013-03-15       Impact factor: 5.705

Review 6.  Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations.

Authors:  C F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients.

Authors:  M J Dooley; S Singh; D Rischin
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.